A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Recruiting now Phase 3 NCT06764485
Run by Celgene · for 18 and older · Men
What this study is about
The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.
Who can join (things the study team will check)
✅ You may be able to join if…
- Participants must have histologic or cytologic confirmation of adenocarcinoma of the prostate without small cell or neuro-endocrine features.
- Participants must have current evidence of metastatic disease documented by either bone lesions on radionuclide bone scan and/or soft tissue lesions on computed tomography/magnetic resonance imaging (CT/MRI).
- Participants must be asymptomatic or mildly symptomatic from prostate cancer with score on Brief Pain Inventory - Short Form (BPI-SF) that must be < 4.
- Participants must have had previous treatment with an androgen receptor pathway inhibitor (abiraterone, enzalutamide, apalutamide, or darolutamide).
🚫 You may not be able to join if…
- Participants must not have impaired cardiac function or clinically significant cardiac disease.
- Participants must not have any brain metastasis.
- Participants must not have any liver metastasis.
- Participants with superscan on technetium-99m (Tc-99m) radionuclide bone scans.
- Other protocol-defined Inclusion/Exclusion criteria apply.
Where this trial is running
- Central Alabama Research, Birmingham, Alabama, United States
- Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
- Local Institution - 0370, Anaheim, California, United States
- Moores Cancer Center, La Jolla, California, United States
- Cancer and Blood Specialty Clinic, Los Alamitos, California, United States
- Local Institution - 0364, Los Angeles, California, United States
- California Pacific Medical Center, San Francisco, California, United States
- San Francisco VA Health Care System, San Francisco, California, United States
- Local Institution - 0458, Santa Rosa, California, United States
- Rocky Mountain Regional VA Medical Center, Aurora, Colorado, United States
- Rocky Mountain Cancer Centers, LLP, Denver, Colorado, United States
- Colorado Clinical Research, Lakewood, Colorado, United States
+ 270 more sites.
Who to contact
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06764485.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.